[{"Assets_0_Q3_USD":866937000.0,"CommonStockSharesOutstanding_0_Q3_shares":357527330.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-430000.0,"NetIncomeLoss_1_Q3_USD":-3462000.0,"NetIncomeLoss_3_Q3_USD":-29713000.0,"StockholdersEquity_0_Q3_USD":595896000.0,"EarningsPerShareBasic_1_Q3_USD":-0.01,"EarningsPerShareBasic_3_Q3_USD":-0.09,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":350994000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":336938000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20191105"}]